{"entity":{"id":"nct05544552","kind":"trial","name":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","aka":["SURF301"],"tldr":"A phase 1/2 trial of TYRA-300 in bladder & urothelial cancer, run by Tyra Biosciences, Inc, active and no longer recruiting.","summary":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations is a phase 1/2 interventional study registered as NCT05544552 by Tyra Biosciences, Inc, with 310 participants enrolled, started 2022-11-22 and due to reach its primary completion in 2026-11. Interventions recorded: TYRA-300.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05544552","url":"https://clinicaltrials.gov/study/NCT05544552"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tyra-300"],"companies":["tyra-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05544552","phase":"1/2","setting":"A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)","sponsor":"Tyra Biosciences, Inc","participation":[{"nct":"NCT05544552","source":"https://clinicaltrials.gov/study/NCT05544552","fetchedAt":"2026-10-07T16:53:45.224Z","studySha256":"44a8edd67b9f3c4249534abd0cdda62c671f07eb706742580d267c5b52a395f7","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-01-12","leadSponsor":"Tyra Biosciences, Inc","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":310,"enrolmentType":"ESTIMATED","siteCount":19,"recruitingSiteCount":0,"countries":["Australia","France","Spain","United States"]}],"started":"2022-11-22","startedType":"actual","enrolled":310,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05544552/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"drug":[{"id":"tyra-300","kind":"drug","name":"TYRA-300","route":"/drugs/tyra-300/"}],"company":[{"id":"tyra-biosciences","kind":"company","name":"Tyra Biosciences","route":"/companies/tyra-biosciences/"}]}}